Insider Transactions in Q1 2026 at Terns Pharmaceuticals, Inc. (TERN)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2026
|
Amy L. Burroughs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
68,749
-9.83%
|
$2,543,713
$37.28 P/Share
|
|
Jan 15
2026
|
Amy L. Burroughs Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,749
+6.37%
|
$274,996
$4.64 P/Share
|
|
Jan 14
2026
|
Amy L. Burroughs Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+34.17%
|
-
|
|
Jan 14
2026
|
Andrew Gengos Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+40.31%
|
-
|
|
Jan 14
2026
|
Emil Kuriakose Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+34.54%
|
-
|
|
Jan 05
2026
|
Amy L. Burroughs Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
71,339
-33.92%
|
$2,710,882
$38.1 P/Share
|
|
Jan 05
2026
|
Amy L. Burroughs Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+41.63%
|
-
|
|
Jan 02
2026
|
Emil Kuriakose Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,155
-1.12%
|
$43,890
$38.98 P/Share
|
|
Jan 02
2026
|
Amy L. Burroughs Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,551
+26.32%
|
$86,204
$4.64 P/Share
|